Web Analytics

3 Latest Announced Rounds

  • $2,500,000
    Unknown

    1 Investors

    Services for Renewable Energy
    Nov 22nd, 2024
  • $3,700,000
    Pre-Series B

    1 Investors

    Financial Services
    Nov 22nd, 2024
  • $45,000,000
    Series C

    1 Investors

    Renewable Energy Semiconductor Manufacturing
    Nov 22nd, 2024
$2,202.93M Raised in 92 Funding Rounds in the past 7 Days - View All

Funding Round Profile

GLOX Therapeutics Ltd.

start up
United Kingdom - Glasgow
  • 15/11/2023
  • Unknown
  • $5,362,000

Glox Therapeutics Ltd. is developing novel precision antibiotics based on protein bacteriocins, which have potent narrow-spectrum activity to target Gram-negative Antimicrobial Resistant (AMR) pathogens.


Related People

James ClarkCo Founder

James Clark United Kingdom - ND

Over the last twenty years Dr James Clark has held leadership positions within Precision Medicine companies including Response Genetics Inc., MDx Health, Enterome, Inivata, Enterobiotix Diadem, and Predictimmune. Most recently as CEO of Glox Therapeutics.

James has a proven track record in precision medicine, within medical device technology and product development in a number of diseases areas(oncology, microbiome, Inflammatory Bowel Disease and Alzheimer’s); as well as developing and implementing over ten successful commercial launches, with exceptional organisation/leadership skills and an extensive industry network.

James has developed over six laboratories in the US and Europe, holding Laboratory Director roles numerous times, and has led CLIA/CAP, ISO 15189 and ISO 13485 approvals

Since 2018 he has been part of the International Scientific Advisory Board for the ICCVs, focussing on the development of cancer vaccines.